NEW YORK – Multi-cancer screening tests that aim to shift diagnosis from later to earlier disease stages are now poised to make their first forays into the clinic, with at least one assay slated to launch during 2021.
Liquid biopsy — the detection of genomic, epigenomic, and other molecular signals of cancer in an individual's blood or other body fluids — has progressed rapidly in recent years expanding from use in late-stage cancer genotyping to a new frontier of early-stage screening in otherwise healthy individuals.